本帖最后由 老马 于 2013-3-13 13:43 编辑 + d& t' E: x6 J" _" ?0 y$ o* x
4 J+ `( u9 V. `: }# ~
健择(吉西他滨)+顺铂+阿瓦斯汀
# L/ w7 x. w. H, P# E) o( r Gemzar +Cisplatin + Avastin
7 e: ^6 i3 C) O0 `# jhttp://annonc.oxfordjournals.org/content/21/9/1804.full3 Q/ s' F0 ^. z: C7 J( r3 Y7 v
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 S- ], i* K! @! NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. # d' W3 N9 s5 T9 U- j
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ; S& O9 w% J8 q: A
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 909)
y: a+ a6 n. S) c: `0 ^+ ^6 z+ c华为网盘附件:; c$ r v8 m8 N5 _
【华为网盘】ava.JPG
* o+ n. W, B) X0 } V |